Faricimab (neovascular age-related macular degeneration) – Benefit assessment according to § 35a Social Code Book V

Report documents

1. Extract of dossier assessment

   Faricimab (neovascular age-related macular degeneration) – Benefit assessment according to § 35a Social Code Book V

   published on

   16.01.2023

   Document type

   PDF document, 310 kB, EN, not accessible

   Download file : Extract of dossier assessment (PDF document, 310 kB, EN, not accessible)
2. Dossier assessment

   Faricimab (neovascular age-related macular degeneration) – Benefit assessment according to § 35a Social Code Book V

   published on

   16.01.2023

   Document type

   PDF document, 645 kB, DE, not accessible

   Download file : Dossier assessment (PDF document, 645 kB, DE, not accessible)

Dossier assessment

Project details

Project no.

A22-110

Commission

Commission awarded on 14.10.2022 by the Federal Joint Committee (GBA).

Report type

Dossier assessment

Status

Commission completed

Department/Division

Drug Assessment

Topic

Head and nerves

Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

Connected Projects

1. Dossier assessment

   Faricimab (visual impairment due to diabetic macular oedema) – Benefit assessment acc. to § 35a Social Code Book V

   Project no.

   A22-109

   Last updated

   16.01.2023

   Status: Commission completed

2. Dossier assessment

   Faricimab (visual impairment due to macular oedema secondary to retinal vein occlusion) – Benefit assessment according to §35a Social Code Book V

   Project no.

   A24-85

   Last updated

   02.12.2024

   Status: Commission completed